Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123408 · ClinicalTrials.gov registry record · NA
Clozapine and Olanzapine Treatment of Aggression
A NA study, sponsored by Nathan Kline Institute for Psychiatric Research.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT01123408: Completed NA study, sponsored by Nathan Kline Institute for Psychiatric Research.
NCT01123408 is a NA study that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01123408, a NA study, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
This was a double-blind randomized study with three treatment arms: clozapine, olanzapine and haloperidol. We compared these three medications in the treatment of aggressive behavior over a 12 week period.
Primary Outcome
The Modified Overt Aggression scale (MOAS) was used to record all aggressive incidents. The primary measure was the total score on the MOAS as well as the score on the MOAS physical aggression subscale
Interventions
- DRUG Haloperidol
- DRUG Olanzapine
- DRUG Clozapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 1999-06 |
| Est. Completion | 2004-07 |
| Phase | NA |
What the finished NCT01123408 record still lists
NCT01123408 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Haloperidol is the first listed.
NCT01123408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01123408 about?
NCT01123408 is a clinical study titled "Clozapine and Olanzapine Treatment of Aggression". This was a double-blind randomized study with three treatment arms: clozapine, olanzapine and haloperidol. We compared these three medications in the treatment of aggressive behavior over a 12 week period.
What is the current status of trial NCT01123408?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 1999-06. Estimated completion is 2004-07.
What interventions are being tested in trial NCT01123408?
The interventions under investigation include: Haloperidol (DRUG), Olanzapine (DRUG), Clozapine (DRUG).
Who is sponsoring clinical trial NCT01123408?
This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01123408's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia